Article | September 20, 2021

Increasing mRNA Capabilities And Capacity For Growing Market Needs

Source: Cytiva

By Sebastian Almeida, Director, CMC, Akron Biotech; Lloyd Jeffs, Director, Clinical Manufacturing Solutions, Precision Nanosystems; John Harmer, Head of Marketing, Aseptic Filling, and Katarina Stenklo, Enterprise Solutions Activation Leader, Cytiva

iStock-1295693740-covid-coronavirus-vaccine-mrna

The rapid development of innovative vaccines allowed for the pharmaceutical industry to deliver its first tools in the fight against the COVID-19 pandemic. The Moderna and Pfizer BioNTech vaccines, which offer 94% efficacy for fully vaccinated adults, both rely on messenger RNA (mRNA).

Even prior to the rise of COVID, with clinical testing of some mRNA vaccines, the ability to “program” mRNA with genetic code to treat/prevent disease has been known for decades. However, the challenges associated with transitioning mRNA into a drug product have hindered its potential.

Now, the success of the mRNA vaccine market is fueling high demand for mRNA, resulting in a critical need to address mRNA manufacturing bottlenecks. As manufacturers across the industry continue to pursue mRNA-based therapies, it is important they understand the challenges they may face in their journey and which solutions could help overcome them.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: